Anzeige
Mehr »
Login
Montag, 09.09.2024 Börsentäglich über 12.000 News von 688 internationalen Medien
Von Null auf 200 Millionen Dollar: Der unaufhaltsame Aufstieg von West Red Lake Gold
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
ACCESSWIRE
599 Leser
Artikel bewerten:
(2)

Cresa Boston: Cresa Manages Corporate Relocation for Global Life Sciences Company Abcam

Global life sciences company moves from Kendall Square to Waltham to support expansion

BOSTON, MA / ACCESSWIRE / July 13, 2021 / The Boston office of Cresa, the world's largest commercial real estate firm representing tenants exclusively, announced today that it was engaged by Abcam for site selection, transaction management, and project management services. As a global life sciences company, Abcam identifies, develops, and distributes high-quality biological reagents and tools that are crucial to research, drug discovery and diagnostics.

Founded and headquartered in Cambridge, England, Abcam opened its first overseas office at One Kendall Square in Cambridge, Mass. in 2003. After outgrowing its current space, Abcam turned to Cresa to locate a larger footprint to support its strategic growth in the United States. Cresa negotiated a 10+-year, 100,000 SF lease at 152 Grove Street in Waltham, Mass. during the early stages of a campus redevelopment, providing Abcam with competitive terms in a rapidly emerging life sciences cluster.

Comprised of workplaces, laboratories, logistics facilities, and building support areas such as loading docks/receiving, Abcam is expected to eventually house approximately 300 of its global 1,600+ employees in Waltham with an expected occupancy transition this summer into the fall.

"Boston is home to a dynamic life sciences community and being an active part of that community is important to Abcam." said Jac Price, Senior Vice President at Abcam. "Our new facility will offer the space and amenities for growth that we need to meet our anticipated demands, while enabling us to actively engage with the life sciences corridors of the Greater Boston region."

"With its expansive startup community, renowned academic and medical institutions, and highly educated workforce, Massachusetts continues to uphold its stature as the best place in the world for the life sciences and attract companies from across the globe," said Kendalle Burlin O'Connell, president and COO, MassBio. "We are so excited to see Abcam expand its presence here, with a new state-of-the-art facility in Waltham - an area well-positioned to become one of the next major clusters within the state."

The Gauge is a former R&D facility located at 152 Grove Street in Waltham which was recently repositioned by Hilco Redevelopment Partners to appeal to growing life science companies. This single-story adaptive re-use features flexible floor plans and Class A amenities, including a fitness center, café, outdoor space, indoor bike storage and ample parking as well as access to public transportation. The landlord worked collaboratively with Abcam in creating a world-class space for its employees and long-term presence in the Greater Boston market for the company.

Abcam partners with life science organizations to co-create novel binders for use in drug discovery, in vitro diagnostics, and therapeutics, driven by the Company's proprietary discovery platforms and world-leading, antibody expertise. With 13 sites globally, many of Abcam's 1,600 strong team are located in the world's leading life science research hubs, complementing a global network of services and support.

Paul Delaney and John Coakley of Cresa Boston negotiated the lease for Abcam, and Mike O'Leary and Duncan Gratton from Cushman Wakefield represented the landlord (Hilco Redevelopment Partners).

The project team includes:

  • Landlord: Hilco Redevelopment Partners
  • Architect: TRIA
  • MEP/FP: R.W. Sullivan
  • General Contractor: JDL Corporate Interiors

About Cresa

Cresa is the world's only global commercial real estate advisory firm that exclusively represents occupiers and specializes in the delivery of fully integrated real estate solutions. Our purpose is to think beyond space, strengthening those we serve and enhancing the quality of life for our clients. Delivered across every industry, Cresa's services include Transaction Management, Workplace Solutions, Project Management, Consulting, Lease Administration, Technology, Investment Banking & Capital Markets and Portfolio Solutions. With over 1000 employees in more than 80 offices globally, Cresa partners with occupiers everywhere. For more information, please visit cresa.com.

Media Contact:

Susan Shelby, FSMPS, CPSM
Rhino PR for Cresa Boston
cresaboston@rhinopr.com
978.985.4541

SOURCE: Cresa Boston



View source version on accesswire.com:
https://www.accesswire.com/655196/Cresa-Manages-Corporate-Relocation-for-Global-Life-Sciences-Company-Abcam

© 2021 ACCESSWIRE
Vorsicht Crash! So sichere ich mein Aktienportfolio aktiv ab

Der schwarze Montag Anfang August, in Folge der temporären Liquidierung des sogenannten „Yen Carry-Trades“, vernichtete Milliarden an Anlegergeldern. Sogenannte Black Swan Events, also Ereignisse, die nichts und niemand vorhersagen kann, traten zuletzt im März 2020 beim Ausbruch der Corona-Pandemie auf.

Doch wie können Sie sich bei einem derartigen Ausverkauf und Verfall Ihres Depots schützen? Im folgenden kostenlosen Spezialreport wird aufgezeigt, wie man sein Depot mit diversen Strategien und den richtigen Instrumenten versichern kann.

Erweitern Sie Ihr Wissen und handeln Sie zukünftig wie die Profis, um vor dem nächsten schwarzen Schwan ihr Kapital in Sicherheit zu bringen.

Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.